Last reviewed · How we verify
NCT04468997
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
Phase 1 trial testing Drug 601 in Wet Age-related Macular Degeneration in 67 participants. Status unknown.
15 March 2021
Quick facts
| Lead sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 67 |
| Start date | 12 November 2018 |
| Primary completion | 15 March 2021 |
| Estimated completion | 15 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Drug 601 — full drug profile →
- Drug 601 — full drug profile →
- Drug 601 — full drug profile →
- Drug 601 — full drug profile →
- Drug 601 — full drug profile →
- Drug 601 — full drug profile →
Conditions studied
- Wet Age-related Macular Degeneration — all drugs for Wet Age-related Macular Degeneration →
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — full company profile →
Who can join
Adults 45 to 80, any sex, with Wet Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04468997
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Wet Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06859515 — A Long-term Follow up Study of EXG102-031 in Participants With wAMD · recruiting
- NCT04645212 — Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] · active not recruiting
- NCT04504123 — MMP-9 Inhibition for Recalcitrant Wet AMD · Phase 2 · recruiting
Other Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. trials
Trials by the same sponsor.
- NCT07507513 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC · Phase 2 · not yet recruiting
- NCT07349329 — A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) · Phase 3 · not yet recruiting
- NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
- NCT07185269 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE · Phase 1, PHASE2 · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04468997 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Last refreshed: 13 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04468997.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing